Is Target Vessel and Device Diameter Important for Results in Peripheral Interventions for Femoropopliteal Artery Disease?
-
Published:2023-08-01
Issue:2
Volume:1
Page:37-42
-
ISSN:2980-261X
-
Container-title:Bulletin of Cardiovasculer Academy
-
language:
-
Short-container-title:kvbulten
Author:
Kaya İbrahim ÇağrıORCID,
Bulut HalilORCID,
Kocaoğlu Alper SelimORCID
Publisher
Galenos Yayinevi
Reference30 articles.
1. 1. Naqvi S, Saqib S, Khan W, Syed I. Rising use of Proton Pump inhibitors: A Karachi perspective. Sci Int (Lahore). 2014;26:1941-4.
2. 2. Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Bmj. 2012 Jan 31;344.
3. 3. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. Jama. 2006 Dec 27;296(24):2947-53..
4. 4. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2008 Aug;28(8):951-9.
5. 5. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why?. The American journal of gastroenterology. 2003 Jan 1;98(1):51-8.